Patents Represented by Attorney, Agent or Law Firm Steven F. Weinstock
-
Patent number: 6297354Abstract: The present invention relates to a class of pentapeptide analogs of LHRH. These compounds are useful in the treatment of disease conditions which are mediated by reproductive hormones, including benign prostate hyperplasia, prostate tumors, breast and ovaries tumors, cryptorchidism, hirsuitism, gastric motility disorders, dysmenorrhea, and endometriosis.Type: GrantFiled: August 12, 1999Date of Patent: October 2, 2001Assignee: Abbott LaboratoriesInventors: Fortuna Haviv, Wesley Dwight, Jonathan Greer
-
Patent number: 5866322Abstract: The present invention includes novel rubella assays employing a Rubella virus capture reagent and a solid phase material containing a reaction site comprising a polymeric cation substance. A test sample suspected of containing Rubella antibody may be contacted with the capture reagent to form a capture reagent/analyte complex. The complex is then contacted to the positively charged solid phase to attract, attach, and immobilize the capture reagent/analyte complex.Type: GrantFiled: October 11, 1991Date of Patent: February 2, 1999Assignee: Abbott LaboratoriesInventors: Yi-Her Jou, Stephen D. Stroupe, Janina Adamczyk, John Safford
-
Patent number: 5478946Abstract: Compounds of the formula: ##STR1## useful as regulators of nitric oxide synthase that indirectly modulate cyclic guanosine monophosphate (cGMP), pharmaceutical compositions thereof, for treating disorders of vascular smooth muscles, macrophages, neurons, platelets, bronchial smooth muscles, optic muscles and gastrointestinal smooth muscles, sickle cell anemia and diabetes.Type: GrantFiled: November 30, 1993Date of Patent: December 26, 1995Assignee: Abbott LaboratoriesInventors: Ferid Murad, James F. Kerwin, Lee D. Gorsky
-
Patent number: 5346907Abstract: Analogs of CCK-tetrapeptides, which analogs have the formula ##STR1## wherein A, B, D, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are specifically defined, having activity as CCK antagonists, useful in the treatment or prevention of disorders of the gastrointestinal, central nervous, appetite regulating or pain regulating systems.Type: GrantFiled: February 16, 1993Date of Patent: September 13, 1994Assignee: Abbott LaboratoriesInventors: James F. Kerwin, Jr., Mark W. Holladay, Michael J. Bennett
-
Patent number: 5340802Abstract: Peptide analog type-B CCK receptor ligands or pharmaceutically-acceptable salts thereof, which are useful for treating central nervous system disorders, substance abuse, gastrointestinal disorders, endocrine disorders, eating-related disorders and for the treatment of shock, respiratory and cardiocirculatory insufficiencies.Type: GrantFiled: January 29, 1993Date of Patent: August 23, 1994Assignee: Abbott LaboratoriesInventors: Kazumi Shiosaki, Alex M. Nadzan, David S. Garvey, Youe-Kong Shue, Mark S. Brodie, Mark W. Holladay, John Y.-L. Chung, Michael D. Tufano, Paul D. May
-
Patent number: 5278176Abstract: Selective and potent nicotinic agonists of the formula: ##STR1## including pharmaceutically-acceptable salts or prodrugs thereof, useful in the treatment of dementias, attentional hyperactivity disorder, anxiety associated with cognitive impairment, or substance abuse withdrawal characterized by decreased cholinergic function.Type: GrantFiled: August 21, 1992Date of Patent: January 11, 1994Assignee: Abbott LaboratoriesInventor: Nan-Horng Lin
-
Patent number: 5272155Abstract: Pharmaceutical compositions comprising a therapeutically effective amount of (+) 2-methylpiperidine and a pharmaceutically-acceptable carrier or diluent, as well as to a method of treating cognitive, neurological and mental disorders, which are characterized by decreased cholinergic function in humans and lower mammals, by administration of (+)2-methylpiperidine, optionally with a nicotinic agonist.Type: GrantFiled: December 5, 1991Date of Patent: December 21, 1993Assignee: Abbott LaboratoriesInventors: Stephen P. Arneric, Michael W. Decker
-
Patent number: 5270302Abstract: Selective and potent Type-A CCK receptor agonists of formula (I):X--Y--Z--Q (I)or a pharmaceutically acceptable salt thereof, wherein,X is selected from ##STR1## Y is selected from ##STR2## Z is ##STR3## and Q is ##STR4## or pharmaceutically-acceptable salts thereof, useful in the treatment of gastrointestinal disorders (including gallbladder disorders), central nervous system disorders, insulin-related disorders and pain, as well as in appetite regulation.Type: GrantFiled: June 17, 1991Date of Patent: December 14, 1993Assignee: Abbott LaboratoriesInventors: Kazumi Shiosaki, Alex M. Nadzan, Hana Kopecka, Youe-Kong Shue, Mark W. Holladay, Chun W. Lin, Hugh N. Nellans
-
Patent number: 5248677Abstract: Compounds of the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein m is 0, 1 or 2 and n is 0 or 1;R.sup.1 is hydrogen or lower alkyl;R.sup.2 is C.sub.1 -C.sub.6 -alkyl substituted with a heterocyclic group or C.sub.7 -C.sub.16 -arylalkyl, wherein the aryl group is unsubstituted or substituted with from one to three non-hydrogen members independently selected from the group consisting of halogen, C.sub.1 -C.sub.6 -alkyl, halo-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, hydroxy, amino and C.sub.1 -C.sub.6 -alkylamino;R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkyl, halogen, and halo-C.sub.1 -C.sub.6 -alkyl, or any two of R.sup.3, R.sup.4, R.sup.5 and R.sup.6 taken together form a methylenedioxy group; andR.sup.7 is hydrogen or C.sub.1 -C.sub.6 -alkyl.Type: GrantFiled: September 18, 1992Date of Patent: September 28, 1993Assignee: Abbott LaboratoriesInventors: Fatima Z. Basha, John F. DeBernardis, Robert J. Altenbach
-
Patent number: 5221675Abstract: Aza-spirocyclic compounds of formula (I) ##STR1## which enhance cortical cholinergic neurotransmission.Type: GrantFiled: February 26, 1991Date of Patent: June 22, 1993Assignee: Abbott LaboratoriesInventors: John Y. L. Chung, David S. Garvey
-
Patent number: 5212326Abstract: This invention concerns certain diethyl- or dipropylacetic acid salts of sodium valproate which have physiological properties similar to those of valproic acid or sodium valproate but show highly superior stability characteristics.Type: GrantFiled: January 7, 1991Date of Patent: May 18, 1993Assignee: Abbott LaboratoriesInventor: Edwin M. Meade
-
Patent number: 5180733Abstract: Compounds of the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein M is 0, 1 or 2 and n is 0 or 1;R.sup.1 is hydrogen or lower alkyl;R.sup.2 is C.sub.1 -C.sub.6 -alkyl substituted with a heterocyclic group or C.sub.7 -C.sub.16 -arylalkyl, wherein the aryl group is unsubstituted or substituted with from one to three non-hydrogen members independently selected from the group consisting of halogen, C.sub.1 -C.sub.6 -alkyl, halo-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, hydroxy, amino and C.sub.1 -C.sub.6 -alkylamino;R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkyl, halogen, and halo-C.sub.1 -C.sub.6 -alkyl, or any two of R.sup.3, R.sup.4, R.sup.5 and R.sup.6 taken together form a methylenedioxy group; andR.sup.7 is hydrogen or C.sub.1 -C.sub.6 -alkyl.Type: GrantFiled: March 22, 1991Date of Patent: January 19, 1993Assignee: Abbott LaboratoriesInventors: Fatima Z. Basha, John F. DeBernardis, Robert J. Altenbach
-
Patent number: 5163993Abstract: A composition and method for thinning Perlette Seedless grape clusters is disclosed. The composition contains a surfactant and a gibberellin. In a method for thinning Perlette Seedless grape clusters, the composition is applied to Perlette Seedless grape clusters during bloom, with the result that clusters are produced that have fewer grapes and in which the grapes are increased in size and weight.Type: GrantFiled: March 26, 1991Date of Patent: November 17, 1992Assignee: Abbott LaboratoriesInventors: Warren E. Shafer, Bala N. Devisetty
-
Patent number: 5158948Abstract: Novel tetracyclic spirobenzazepine compounds of the formula ##STR1## or a pharmaceutically-acceptable salt, amide or ester thereof, which are dopamine D-1 receptor antagonists useful for treating dopamine-related neurological and psychological disorders, cognitive impairment, attention deficit disorders and addictive behavior disorders.Type: GrantFiled: September 19, 1991Date of Patent: October 27, 1992Assignee: Abbott LaboratoriesInventors: Robert W. Schoenleber, Paul P. Ehrlich, John W. Kebabian, James R. Campbell
-
Patent number: 5149784Abstract: A process for the manufacture of vancomycin which does not require preparation of a phosphate intermediate. The process consists of loading a vancomycin onto a suitable adsorbent and eluting the vancomycin solution therefrom with an ammonium solvent followed by loading the solution onto a second adsorbent and eluting the purified, vancomycin therefrom with a solvent of alcohol and acid. The purified vancomycin is then crystallized by adding a base solution in an amount sufficient to raise the pH of the vancomycin/base solution to a pH of about 9.5 to 10.5 followed by the addition of an organic solvent such as methanol. The crystallized vancomycin is then reslurried in an aqueous solution and then recrystallized by adding a base solution in an amount sufficient to raise the pH to about 9.5 to about 10.5, followed by the addition of an organic solvent such as methanol. The recrystallized vancomycin is dissolved and titrated with hydrochloric acid to a pH of about 3.0 to 3.5.Type: GrantFiled: July 10, 1990Date of Patent: September 22, 1992Assignee: Abbott LaboratoriesInventor: Alexander H. T. Chu
-
Patent number: 5140014Abstract: The present invention is directed to the production and utilization of novel antibiotic compounds. These compounds are derivatives of the antibacterial agents tylosin and rosaramicin and exert a broad spectrum antibiotic activity toward several bacterial strains. Pharmaceutical compositions and methods of treating bacterial infections are described.Type: GrantFiled: November 13, 1989Date of Patent: August 18, 1992Assignee: Abbott LaboratoriesInventors: Clarence J. Maring, Paul A. Lartey, Leslie A. Freiberg
-
Patent number: 5128346Abstract: A compound of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are substituents; R.sub.6 is hydrogen, loweralkyl, cycloalkyl, loweralkenyl, arylalkyl, (substituted aryl)alkyl, or (heterocyclic)alkyl; B is a bond, an alkylene group, an alkenylene group, an alkadienylene group or a heteroatom containing linking group; D is a substituted acyl group or tetrazolyl; Z is CO, C(S) or S(O).sub.2 ; Ar is a heterocyclic group; and n is 1 to 3.Also disclosed are a composition and a method for antagonizing CCK, a composition and method for treating or preventing gastrointestinal, central nervous, appetite regulating and pain regulating systems, a composition and method for treating or preventing hyperinsulinemia, methods of making the compounds and intermediates useful in making the compounds.Type: GrantFiled: August 23, 1990Date of Patent: July 7, 1992Assignee: Abbott LaboratoriesInventors: Alex M. Nadzan, James F. Kerwin, Chun W. Lin
-
Patent number: 5085864Abstract: An injectable drug composition including a therapeutically effective amount of a lipophilic drug and a bile salt.Type: GrantFiled: May 20, 1991Date of Patent: February 4, 1992Assignee: Abbott LaboratoriesInventors: John B. Cannon, Chung-Chiang Hsu, Karen J. Papp, N. Adeyinka Williams
-
Patent number: 5075289Abstract: Semisynthetic antibiotics with improved therapeutic properties are disclosed. In particular, 9-R-azacyclic derivatives of erythromycin, its derivatives, and their salts and esters show superior antimicrobial activity compared to other macrolide compounds.Type: GrantFiled: June 7, 1988Date of Patent: December 24, 1991Assignee: Abbott LaboratoriesInventors: Richard J. Pariza, Paul A. Lartey, Clarence J. Maring, Larry L. Klein
-
Patent number: D399106Type: GrantFiled: July 2, 1997Date of Patent: October 6, 1998Inventor: Herbert Wexler